

Atrium Health Infusion

Referral Status:	New Start ☐ Order Change ☐ Renewal
Preferred Location:	☐ Atrium Health Infusion Center Concord Fax: 704-468-3401
	Atrium Health Infusion Center Pineville Fax: 704-468-3401
	☐ Atrium Health Infusion Center Southpark Fax: 704-468-3401
	☐ Atrium Health Infusion Center Huntersville Fax: 704-468-3401
	Atrium Health Infusion Center Kenilworth, a facility of CMC Fax: 704-512-5390
	Atrium Health Infusion Center Abbey Place, a facility of CMC Fax: 704-512-5390
	Atrium Health Infusion Center Cabarrus, a facility of CMC Fax: 704-512-5390

Center		Atrium Health Infusion Center Cabarrus, a facility of CMC Fax: 704-512-5390
		Ocrevus® (ocrelizumab) Infusion Order (Revised 10/14/2025)
		All orders with a √ will be placed.
Patient Demographics: Patient Name:	Date of Birth:	MRN:
Address:	Date of Birth.	riniv.
City:	State:	Zip Code:
Allergies: (please list all allergie	es or attach list)	
NKDA Diagnosis: (Complete the 2nd	and/or 3rd Digits of the ICD-10)	
G35.A - Relapsing-Remitting		G35.B0 - Primary Progressive MS, unspecified
G35.B1 - Active Primary Pro		G35.B2 - Non-Active Primary Progressive MS
G35.C1 - Active Secondary Required Documentation: (req	•	Other:
Patient Demographic Sheet	quired prior to scrieddaing j	If the patient is new to the ordered therapy, indicate washout from previous therapy:
Copy of Insurance Card (front and back)		
Most Recent Labs (must include labs pertinent to medication ordered)		□ No Washout Needed
Consult Note or last 2 Office Visits with referring provider or APP		If the patient is currently on the therapy, indicate date of last infusion: Next infusion due date:
Complete Medication List - Include all tried and failed meds		If this is an order change only, indicate if the current therapy should be administered until insurance approval is received for the new request.
Diagnostic Studies Pertinent to Medication Ordered		Yes No
Treatment Parameters:		
Hold treatment and notify p	provider IF:	
- Temperature is GREATER 1		
 Patient complains of symp Patient is taking an antibio 	otoms of acute viral or bacterial infection;	
- Patient presents with signs	s of PML (Progressive Multifocal Leukoencep	halopathy) such as progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, changes in thinking, memory, and
Required lab results:	ision and personality changes.	
1 '	OR to FIRST Treatment and then annually;	
- CBC w/ Diff within 90 days		
 LFTs within 90 days PRIOR Serum Creatinine within 9 		
Hold treatment and notify p		
- Hepatitis B Panel: POSITIV		
 ANC LESS THAN 700 or no LFTs ABNORMAL or not on 		
 Serum Creatinine ABNORI 	MAL OF NOT ON TILE.	
- Serum Creatinine ABNORI Provider Communication:	MAL or not on file.	
Provider Communication: Vaccination with live-attent	uated or live vaccines is not recommended d	uring treatment with ocrelizumab and after discontinuation, until B-cell repletion. Ensure all immunizations, according to immunization guidelines,
Provider Communication: Vaccination with live-attent	uated or live vaccines is not recommended d	uring treatment with ocrelizumab and after discontinuation, until B-cell repletion. Ensure all immunizations, according to immunization guidelines, t for live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines.
Provider Communication: Vaccination with live-attenuare complete at least 4 week	uated or live vaccines is not recommended di eks prior to initiation of ocrelizumab treatmen	
Provider Communication: Vaccination with live-attent are complete at least 4 wee During treatment with ocrel	uated or live vaccines is not recommended di eks prior to initiation of ocrelizumab treatmen lizumab monitor patients for signs and sympt	t for live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information.
Provider Communication: Vaccination with live-attent are complete at least 4 wee During treatment with ocrel Monitor the levels of quanti	uated or live vaccines is not recommended deks prior to initiation of ocrelizumab treatmen lizumab monitor patients for signs and sympt tative serum immunoglobulins during ocreliz	t for live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections.
Provider Communication: Vaccination with live-attent are complete at least 4 wee During treatment with ocrel Monitor the levels of quanti - Consider discontinuing oc	uated or live vaccines is not recommended deks prior to initiation of ocrelizumab treatmen lizumab monitor patients for signs and sympt tative serum immunoglobulins during ocreliz	t for live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information.
Provider Communication: Vaccination with live-attent are complete at least 4 wee During treatment with ocrel Monitor the levels of quanti - Consider discontinuing oc	uated or live vaccines is not recommended di ks prior to initiation of ocrelizumab treatmen lizumab monitor patients for signs and sympt tative serum immunoglobulins during ocreliz crelizumab therapy in patients with serious op	t for live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections. oportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins.
Provider Communication: Vaccination with live-attent are complete at least 4 wee During treatment with ocrel Monitor the levels of quanti - Consider discontinuing oc Nursing Communication: Start PIV/Access CVC and f	uated or live vaccines is not recommended deks prior to initiation of ocrelizumab treatmen lizumab monitor patients for signs and sympt tative serum immunoglobulins during ocrelizerelizumab therapy in patients with serious of the latter per approved Atrium Health prot	t for live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections. oportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins.
Provider Communication: Vaccination with live-attent are complete at least 4 wee During treatment with ocrel Monitor the levels of quanti - Consider discontinuing oc Nursing Communication: Start PIV/Access CVC and f	uated or live vaccines is not recommended deks prior to initiation of ocrelizumab treatmen lizumab monitor patients for signs and sympt tative serum immunoglobulins during ocrelizerelizumab therapy in patients with serious of the latter per approved Atrium Health prot	t for live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections. oportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins.
Provider Communication: Vaccination with live-attent are complete at least 4 wee During treatment with ocrel Monitor the levels of quanti - Consider discontinuing oc Nursing Communication: Start PIV/Access CVC and f Obtain vital signs PRIOR to: Infuse using a 0.2 micron in	uated or live vaccines is not recommended deks prior to initiation of ocrelizumab treatmen lizumab monitor patients for signs and sympt tative serum immunoglobulins during ocreliz crelizumab therapy in patients with serious of llush device per approved Atrium Health prot treatment, 30 minutes POST initiation of treal-line filter.	t for live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections. oportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. ocol. tment, every 60 minutes for the remainder of treatment, and 60 minutes POST treatment.
Provider Communication: Vaccination with live-attent are complete at least 4 wee During treatment with ocrel Monitor the levels of quanti-consider discontinuing oc Nursing Communication: Start PIV/Access CVC and f Obtain vital signs PRIOR to Infuse using a 0.2 micron in Monitor patient for signs of	uated or live vaccines is not recommended dicks prior to initiation of ocrelizumab treatment lizumab monitor patients for signs and symptotative serum immunoglobulins during ocrelizorelizumab therapy in patients with serious of the device per approved Atrium Health prototreatment, 30 minutes POST initiation of trearl-line filter.	t for live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections. oportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. ocol. treatment, every 60 minutes for the remainder of treatment, and 60 minutes POST treatment.
Provider Communication: Vaccination with live-attent are complete at least 4 wee During treatment with ocrel Monitor the levels of quanti - Consider discontinuing oc Nursing Communication: Start PIV/Access CVC and f Obtain vital signs PRIOR to Infuse using a 0.2 micron in Monitor patient for signs of Pre-Medications: (Administer	uated or live vaccines is not recommended dieks prior to initiation of ocrelizumab treatmen lizumab monitor patients for signs and sympt tative serum immunoglobulins during ocrelizorelizumab therapy in patients with serious operations of the device per approved Atrium Health prot treatment, 30 minutes POST initiation of treatment in the filter. The filter in the	t for live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections. oportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. ocol. treatment, every 60 minutes for the remainder of treatment, and 60 minutes POST treatment.
Provider Communication: Vaccination with live-attent are complete at least 4 wee During treatment with ocrel Monitor the levels of quanti-consider discontinuing oc Nursing Communication: Start PIV/Access CVC and f Obtain vital signs PRIOR to Infuse using a 0.2 micron in Monitor patient for signs of	uated or live vaccines is not recommended disks prior to initiation of ocrelizumab treatmentizumab monitor patients for signs and sympt tative serum immunoglobulins during ocreliz cretizumab therapy in patients with serious of the distribution of the distribution of treatment, 30 minutes POST initiation of treatment filter. -line filter. -line filter. -reaction or side effects for 60 minutes POST-all pre-medications 30mins prior to treatmonoming PO ONCE	t for live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections. oportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. ocol. treatment, every 60 minutes for the remainder of treatment, and 60 minutes POST treatment.
Provider Communication: Vaccination with live-attent are complete at least 4 wee During treatment with ocret Monitor the levels of quanti - Consider discontinuing oc Nursing Communication: Start PIV/Access CVC and f Obtain vital signs PRIOR to Infuse using a 0.2 micron in Monitor patient for signs of Pre-Medications: (Administer Acetaminophen (Tylenol) 1! Diphenhydramine (Benadry	uated or live vaccines is not recommended dicks prior to initiation of ocrelizumab treatmentizumab monitor patients for signs and symptotative serum immunoglobulins during ocrelizorelizumab therapy in patients with serious operations of the serious of the serio	t for live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections. oportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. ocol. treatment, every 60 minutes for the remainder of treatment, and 60 minutes POST treatment.
Provider Communication: Vaccination with live-attent are complete at least 4 wee During treatment with ocrel Monitor the levels of quanti - Consider discontinuing oc Nursing Communication: Start PIV/Access CVC and f Obtain vital signs PRIOR to Monitor patient for signs of Pre-Medications: (Administer Acetaminophen (Tylenol) 1 Diphenhydramine (Benadry Diphenhydramine (Benadry Loratadine (Claritin) 10mg I	uated or live vaccines is not recommended disks prior to initiation of ocrelizumab treatmen lizumab monitor patients for signs and sympt tative serum immunoglobulins during ocrelizorelizumab therapy in patients with serious op flush device per approved Atrium Health prot treatment, 30 minutes POST initiation of treatment, and minutes POST initiation or side effects for 60 minutes POST-all pre-medications 30mins prior to treatment, 30 prior to treatment, 3	t for live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections. oportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. ocol. treatment, every 60 minutes for the remainder of treatment, and 60 minutes POST treatment. treatment ent)
Provider Communication: Vaccination with live-attent are complete at least 4 wee During treatment with ocrel Monitor the levels of quanti - Consider discontinuing oc Nursing Communication: Start PIV/Access CVC and f Obtain vital signs PRIOR to Monitor patient for signs of Pre-Medications: (Administer Acetaminophen (Tylenol) 1 Diphenhydramine (Benadry Diphenhydramine (Claritin) 10mg I Methylprednisolone sodiun	uated or live vaccines is not recommended dicks prior to initiation of ocrelizumab treatmentizumab monitor patients for signs and symptotative serum immunoglobulins during ocrelizorelizumab therapy in patients with serious operations of the serious of the serio	t for live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections. oportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. ocol. treatment, every 60 minutes for the remainder of treatment, and 60 minutes POST treatment. treatment ent)
Provider Communication: ✓ Vaccination with live-attent are complete at least 4 wee ✓ During treatment with ocrel ✓ Monitor the levels of quanti - Consider discontinuing oc Nursing Communication: ✓ Start PIV/Access CVC and f ✓ Obtain vital signs PRIOR to ✓ Infuse using a 0.2 micron in ✓ Monitor patient for signs of Pre-Medications: (Administer ↑ Acetaminophen (Tylenol) 1 ↑ Diphenhydramine (Benadry ↑ Diphenhydramine (Benadry ↑ Loratadine (Claritin) 10mg ↑ Methylprednisolone sodium ↑ Methylprednisolone sodium Infusion Therapy:	uated or live vaccines is not recommended disks prior to initiation of ocrelizumab treatmen lizumab monitor patients for signs and sympt tative serum immunoglobulins during ocreliz crelizumab therapy in patients with serious of flush device per approved Atrium Health prot treatment, 30 minutes POST initiation of treatment,	t for live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections. oportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. ocol. treatment, every 60 minutes for the remainder of treatment, and 60 minutes POST treatment. treatment ent)
Provider Communication: ✓ Vaccination with live-attent are complete at least 4 wee ✓ During treatment with ocret ✓ Monitor the levels of quanti - Consider discontinuing oc Nursing Communication: ✓ Start PIV/Access CVC and f ✓ Obtain vital signs PRIOR to ✓ Infuse using a 0.2 micron in ✓ Monitor patient for signs of Pre-Medications: (Administer Acetaminophen (Tylenol) 1 □ Diphenhydramine (Benadry □ Diphenhydramine (Benadry □ Loratadine (Claritin) 10mg l □ Methylprednisolone sodiun Methylprednisolone sodiun	uated or live vaccines is not recommended disks prior to initiation of ocrelizumab treatmen lizumab monitor patients for signs and sympt tative serum immunoglobulins during ocreliz crelizumab therapy in patients with serious of flush device per approved Atrium Health prot treatment, 30 minutes POST initiation of treatment, 30 minutes POST initiation or side effects for 60 minutes POST-all pre-medications 30mins prior to treatm 000mg PO ONCE (1) 25mg PO ONCE (2) 25mg IV ONCE (3) 25mg IV ONCE (4) 25mg IV ONCE (5) an succinate (Solu-Medrol) 125mg IV ONCE (5) 20mg IV week 0 and week 2	t for live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections. oportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. ocol. treatment, every 60 minutes for the remainder of treatment, and 60 minutes POST treatment. treatment ent)
Provider Communication: Vaccination with live-attent are complete at least 4 wee During treatment with ocrel Monitor the levels of quanti - Consider discontinuing oc Nursing Communication: Start PIV/Access CVC and f Obtain vital signs PRIOR to Influse using a 0.2 micron in Monitor patient for signs of Pre-Medications: (Administer Acetaminophen (Tylenol) 1 Diphenhydramine (Benadry Loratadine (Claritin) 10mg Methylprednisolone sodiun Methylprednisolone sodiun Methylprednisolone sodiun Infusion Therapy: Ccrelizumab (Ocrevus) 300 Ocrelizumab (Ocrevus) 600	uated or live vaccines is not recommended disks prior to initiation of ocrelizumab treatmen lizumab monitor patients for signs and sympt tative serum immunoglobulins during ocreliz crelizumab therapy in patients with serious of flush device per approved Atrium Health prot treatment, 30 minutes POST initiation of treatment,	t for live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections. oportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. ocol. treatment, every 60 minutes for the remainder of treatment, and 60 minutes POST treatment. treatment ent)
Provider Communication: Vaccination with live-attent are complete at least 4 wee During treatment with ocrel Monitor the levels of quanti - Consider discontinuing oc Nursing Communication: Start PIV/Access CVC and f Obtain vital signs PRIOR to Influse using a 0.2 micron in Monitor patient for signs of Pre-Medications: (Administer Acetaminophen (Tylenol) 1 Diphenhydramine (Benadry Loratadine (Claritin) 10mg Methylprednisolone sodiun Methylprednisolone sodiun Methylprednisolone sodiun Infusion Therapy: Ccrelizumab (Ocrevus) 300 Ocrelizumab (Ocrevus) 600	uated or live vaccines is not recommended disks prior to initiation of ocrelizumab treatmen lizumab monitor patients for signs and sympt tative serum immunoglobulins during ocreliz relizumab therapy in patients with serious of flush device per approved Atrium Health prot treatment, 30 minutes POST initiation of the post	t for live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections. opportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. ocol. tment, every 60 minutes for the remainder of treatment, and 60 minutes POST treatment. treatment ent) chloride 0.9% 100mL IVPB
Provider Communication: ✓ Vaccination with live-attent are complete at least 4 wee ✓ During treatment with ocret ✓ Monitor the levels of quantiting communication: ✓ Start PIV/Access CVC and for the levels of quantiting communication: ✓ Obtain vital signs PRIOR to the levels of quantiting communication: ✓ Infuse using a 0.2 micron in the levels of quantiting communication: ✓ Infuse using a 0.2 micron in the levels of quantiting communication: ✓ Infuse using a 0.2 micron in the levels of the le	uated or live vaccines is not recommended disks prior to initiation of ocrelizumab treatmentizumab monitor patients for signs and sympt tative serum immunoglobulins during ocrelizorelizumab therapy in patients with serious operations of the serious operation of the serio	t for live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections. opportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. ocol. tment, every 60 minutes for the remainder of treatment, and 60 minutes POST treatment. treatment ent) chloride 0.9% 100mL IVPB full maintenance (600mg) dose, if no previous infusion reaction OR following 2 subsequent 600mg doses with no infusion reaction. See PI for rates.
Provider Communication: Vaccination with live-attent are complete at least 4 wee During treatment with ocret Monitor the levels of quanti - Consider discontinuing oc Nursing Communication: Start PIV/Access CVC and f Obtain vital signs PRIOR to Monitor patient for signs of Pre-Medications: (Administer Acetaminophen (Tylenol) 1 Diphenhydramine (Benadry Diphenhydramine (Benadry Methylprednisolone sodiun Methylprednisolone sodiun Methylprednisolone sodiun Infusion Therapy: Ocretizumab (Ocrevus) 600 Rapid Ocretizumab (Ocrevus) 600 Rapid Ocretizumab (Ocrevus) 600 Supportive Care Medications: Ibuprofen (Motrin) 800mg P Ondansetron (Zofran) 4mg	uated or live vaccines is not recommended disks prior to initiation of ocrelizumab treatmentizumab monitor patients for signs and sympt tative serum immunoglobulins during ocrelizorelizumab therapy in patients with serious operations of the serious operation of the serio	t for live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections. opportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. ocol. tment, every 60 minutes for the remainder of treatment, and 60 minutes POST treatment. treatment ent) chloride 0.9% 100mL IVPB full maintenance (600mg) dose, if no previous infusion reaction OR following 2 subsequent 600mg doses with no infusion reaction. See PI for rates.
Provider Communication: Vaccination with live-attent are complete at least 4 wee During treatment with ocrel Monitor the levels of quanti - Consider discontinuing oc Nursing Communication: Start PIV/Access CVC and f Obtain vital signs PRIOR to Infuse using a 0.2 micron in Monitor patient for signs of Pre-Medications: (Administer Acetaminophen (Tylenol) 1 Diphenhydramine (Benadry Diphenhydramine (Benadry Loratadine (Claritin) 10mg 1 Methylprednisolone sodiun Infusion Therapy: Ocrelizumab (Ocrevus) 600 Rapid Ocrelizumab (Ocrevus) 600 Rapid Ocrelizumab (Ocrevus) 600 Ondansetron (Zofran) 4mg Hypersensitivity Protectly Initiate Afrium Health approf	uated or live vaccines is not recommended disks prior to initiation of ocrelizumab treatmen lizumab monitor patients for signs and sympt tative serum immunoglobulins during ocreliz relizumab therapy in patients with serious of flush device per approved Atrium Health prot treatment, 30 minutes POST initiation of treatment, 30 minutes POST initiation of treatment, 30 minutes POST initiation of treatment of side effects for 60 minutes POST-all pre-medications 30 mins prior to treatment on the properties of the pro	t for live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections. apportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. ocol. treatment, every 60 minutes for the remainder of treatment, and 60 minutes POST treatment. treatment ent) chloride 0.9% 100mL IVPB full maintenance (600mg) dose, if no previous infusion reaction OR following 2 subsequent 600mg doses with no infusion reaction. See PI for rates. in (4-6). Give second after acetaminophen.
Provider Communication: Vaccination with live-attent are complete at least 4 wee During treatment with ocret Monitor the levels of quanti - Consider discontinuing oc Nursing Communication: Start PIV/Access CVC and f Obtain vital signs PRIOR to Infuse using a 0.2 micron in Monitor patient for signs of Pre-Medications: (Administer Acetaminophen (Tylenol) 1 Diphenhydramine (Benadry Diphenhydramine (Benadry Loratadine (Claritin) 10mg I Methylprednisolone sodiun Ocrelizumab (Ocrevus) 300 Ocrelizumab (Ocrevus) 600 Rapid Ocrelizumab (Ocrevus) 600 Rapid Ocrelizumab (Ocrevus) 600 Ondansetron (Zofran) 4mg Hypersensitivity Protocol: Initiate Atrium Health approves website at atriumhealth.org	uated or live vaccines is not recommended disks prior to initiation of ocrelizumab treatmen lizumab monitor patients for signs and sympt tative serum immunoglobulins during ocreliz redizumab therapy in patients with serious of flush device per approved Atrium Health prot treatment, 30 minutes POST initiation of treatment, 30 minutes POST initiation of treatment, 30 minutes POST initiation of treatment in the filter. In efilter. In efilter. In English of the side of t	t for live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections. opportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. ocol. tment, every 60 minutes for the remainder of treatment, and 60 minutes POST treatment. treatment ent) chloride 0.9% 100mL IVPB full maintenance (600mg) dose, if no previous infusion reaction OR following 2 subsequent 600mg doses with no infusion reaction. See PI for rates.
Provider Communication: Vaccination with live-attent are complete at least 4 wee During treatment with ocret Monitor the levels of quanti - Consider discontinuing oc Nursing Communication: Start PIV/Access CVC and f Obtain vital signs PRIOR to Infuse using a 0.2 micron in Monitor patient for signs of Pre-Medications: (Administer Acetaminophen (Tylenol) 1 Diphenhydramine (Benadry Diphenhydramine (Benadry Loratadine (Claritin) 10mg 1 Methylprednisolone sodiun Methylprednisolone sodiun Infusion Therapy: Ocrelizumab (Ocrevus) 600 Rapid Ocrelizumab (Ocrevus) 600 Rapid Ocrelizumab (Ocrevus) 600 Ondansetron (Zofran) 4mg Hypersensitivity Protocol: Initiate Atrium Health approvebsite at atriumhealth.org Prescriber Information:	uated or live vaccines is not recommended disks prior to initiation of ocrelizumab treatmen lizumab monitor patients for signs and sympt tative serum immunoglobulins during ocreliz redizumab therapy in patients with serious of flush device per approved Atrium Health prot treatment, 30 minutes POST initiation of treatment, 30 minutes POST initiation of treatment, 30 minutes POST initiation of treatment in the filter. In efilter. In efilter. In English of the side of t	tor live or live-attenuated vaccines, and at least 2 weeks prior to initiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections. apportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. ocol. treatment, every 60 minutes for the remainder of treatment, and 60 minutes POST treatment. treatment ent) full maintenance (600mg) dose, if no previous infusion reaction OR following 2 subsequent 600mg doses with no infusion reaction. See PI for rates. in (4-6). Give second after acetaminophen.
Provider Communication: Vaccination with live-attent are complete at least 4 week During treatment with ocrel Monitor the levels of quantic Consider discontinuing oc Start PIV/Access CVC and for Mursing Communication: Start PIV/Access CVC and for Monitor patient for signs of Pre-Medications: (Administer Acetaminophen (Tylenol) 11 Diphenhydramine (Benadry Diphenhydramine (Benadry Corelizumab (Ocrevis) 300 Methylprednisolone sodium Infusion Therapy: Ocrelizumab (Ocrevus) 600 Rapid Ocrelizumab (Ocrevus) 600 Rapid Ocrelizumab (Ocrevus) 600 Rapid Ocrelizumab (Ocrevus) 600 Initiate Atrium Health approve Medications: Initiate Atrium Health approvensible Information: Prescriber Information: Provider Name:	uated or live vaccines is not recommended disks prior to initiation of ocrelizumab treatmen lizumab monitor patients for signs and sympt tative serum immunoglobulins during ocreliz redizumab therapy in patients with serious of flush device per approved Atrium Health prot treatment, 30 minutes POST initiation of treatment, 30 minutes POST initiation of treatment, 30 minutes POST initiation of treatment in the filter. In efilter. In efilter. In English of the side of t	tor live or live-attenuated vaccines, and at least 2 weeks prior to initiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections. sportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. ocol. treent, every 60 minutes for the remainder of treatment, and 60 minutes POST treatment. treatment ent) full maintenance (600mg) dose, if no previous infusion reaction OR following 2 subsequent 600mg doses with no infusion reaction. See PI for rates. in (4-6). Give second after acetaminophen. Phone: Fax:
Provider Communication: Vaccination with live-attent are complete at least 4 wee During treatment with ocret Monitor the levels of quanti - Consider discontinuing oc Nursing Communication: Start PIV/Access CVC and f Obtain vital signs PRIOR to Infuse using a 0.2 micron in Monitor patient for signs of Pre-Medications: (Administer Acetaminophen (Tylenol) 1 Diphenhydramine (Benadry Diphenhydramine (Benadry Loratadine (Claritin) 10mg 1 Methylprednisolone sodiun Methylprednisolone sodiun Infusion Therapy: Ocrelizumab (Ocrevus) 600 Rapid Ocrelizumab (Ocrevus) 600 Rapid Ocrelizumab (Ocrevus) 600 Ondansetron (Zofran) 4mg Hypersensitivity Protocol: Initiate Atrium Health approvebsite at atriumhealth.org Prescriber Information:	uated or live vaccines is not recommended disks prior to initiation of ocrelizumab treatmen lizumab monitor patients for signs and sympt tative serum immunoglobulins during ocreliz redizumab therapy in patients with serious of flush device per approved Atrium Health prot treatment, 30 minutes POST initiation of treatment, 30 minutes POST initiation of treatment, 30 minutes POST initiation of treatment in the filter. In efilter. In efilter. In English of the side of t	tor live or live-attenuated vaccines, and at least 2 weeks prior to initiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections. apportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. ocol. treatment, every 60 minutes for the remainder of treatment, and 60 minutes POST treatment. treatment ent) full maintenance (600mg) dose, if no previous infusion reaction OR following 2 subsequent 600mg doses with no infusion reaction. See PI for rates. in (4-6). Give second after acetaminophen.
Provider Communication: Vaccination with live-attent are complete at least 4 week During treatment with ocret Monitor the levels of quantic Consider discontinuing octor of the consideration of th	uated or live vaccines is not recommended disks prior to initiation of ocrelizumab treatmen lizumab monitor patients for signs and sympt tative serum immunoglobulins during ocreliz crelizumab therapy in patients with serious op flush device per approved Atrium Health prot treatment, 30 minutes POST initiation of treatment, 30 minutes POST initiation of treatment, 30 minutes POST initiation of treatment in the fluter. Treaction or side effects for 60 minutes POST-all pre-medications 30mins prior to treatment in the protection of the process	tror live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections, apportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. ocol. treatment, every 60 minutes for the remainder of treatment, and 60 minutes POST treatment. treatment ent) full maintenance (600mg) dose, if no previous infusion reaction OR following 2 subsequent 600mg doses with no infusion reaction. See PI for rates. in (4-6). Give second after acetaminophen. an acute adverse or anaphylactic infusion/injection reaction. The hypersensitivity protocol can be found on the Atrium Health Infusion Center Phone: Fax: NPI: Office Contact: Office Contact: Office Contact Phone Number:
Provider Communication: Vaccination with live-attent are complete at least 4 week During treatment with ocret Monitor the levels of quantities of consider discontinuing octors of the consideration of the considerat	uated or live vaccines is not recommended disks prior to initiation of ocrelizumab treatmen lizumab monitor patients for signs and sympt tative serum immunoglobulins during ocreliz redizumab therapy in patients with serious of flush device per approved Atrium Health prot treatment, 30 minutes POST initiation of treatment, 30 minutes POST initiation of treatment, 30 minutes POST initiation of treatment in the filter. In efilter. In efilter. In English of the side of t	tror live or live-attenuated vaccines, and at least 2 weeks prior to intiation of ocrelizumab for non-live vaccines. oms of PML and immune-mediated colitis. Refer to prescribing information. umab treatment and after discontinuation of treatment, until B-cell repletion, especially in the setting of recurrent serious infections, apportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. ocol. treatment, every 60 minutes for the remainder of treatment, and 60 minutes POST treatment. treatment ent) full maintenance (600mg) dose, if no previous infusion reaction OR following 2 subsequent 600mg doses with no infusion reaction. See PI for rates. in (4-6). Give second after acetaminophen. an acute adverse or anaphylactic infusion/injection reaction. The hypersensitivity protocol can be found on the Atrium Health Infusion Center Phone: Fax: NPI: Office Contact: Office Contact: Office Contact Phone Number: